The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Milan, Italy
11-50 Employees
1987
Since 1987, Clonit has been focused in developing, manufacturing and distributing of innovative and reliable in Vitro Diagnostic Equipment and Reagents for Molecular Diagnostics. Founded in 1987, Clonit srl was one of the first Italian companies operating in the field of biotechnology. Il Gruppo Clonit, distributore esclusivo per l’Italia di BioVendor R&D®, annuncia il lancio del nuovo kit fastGEN TP53. Clonit will exhibit at Hall 3 – C60. A deep expertise in Molecular Biology mixed to our strong culture of business ethics make our company a valued partner for laboratories and hospitals around the world. Our clinical diagnostic products are used to detect a broad range of diseases in several key areas such as viral, bacterial and fungal infections (including sexually transmitted diseases, transplantation/immunocompromised related infections, tropical diseases, healthcare associated infections), thrombophilia, oncohematology and several genetic disorders. The standardization of internal quality control system and cross-checks in external reference labs allow Clonit to ensure application of the highest standards of care and quality (ISO 9001 and ISO 13485 Certified). Since from the beginning the company has worked to develope innovative and reliable analytical methods in the field of In Vitro diagnostics using molecular biology techinques.
+
Featured
Pharmacogenomic
... Pharmacogenomic ...
Southampton, United Kingdom
1-10 Employees
We are a uniquely positioned team of DNA experts dedicated to applying next generation DNA sequencing to crime fighting and family DNA testing. We are a uniquely positioned team of DNA experts dedicated to applying the next generation in DNA technologies to forensics, family DNA testing, and clinical molecular diagnostics. FGIH analyses crime scene related samples using a technology called next generation sequencing (NGS) sometimes referred to as massive parallel sequencing (MPS). We are offering the Fit to Fly Test (guidelines from the DHSC on Covid-19 testing and travel) as well as asymptomatic general testing. With solutions and support to forensics and families FGIH is also an open door training facility supporting academia giving the medical/forensic scientists of the future access to the technologies of the future. Caroline, aka the Duracellbunny, founded the Forensic Genomics Innovation Hub in 2020 just as COVID-19 was declared a pandemic. Never short on energy Caroline enjoys not only running, but is also passionate about driving forensic science, consumer genetics and research forward. Mich is a consultant in Paediatric Allergy and Immunology at Southampton Children’s Hospital, a World Allergy Organization National Centre of Excellence.
+
Featured
Pharmacogenomics Test
... Pharmacogenomics Test – Forensic Genomics Innovation ...
Austin, United States
11-50 Employees
2012
It is our mission to stay ahead of the curve by constantly building our infrastructure, laboratory, and methods. Gene By Gene was founded in 2000, specializing in DNA-based ancestry and genealogy as FamilyTreeDNA. Our expertise in this field has led to many prestigious relationships along the way, including an exclusive partnership as the testing provider for National Geographic’s Genographic Project. Through FamilyTreeDNA, Gene By Gene built an incredible laboratory and an incredible staff of experts. With a team of leaders and technicians from leading institutions and a wealth of experience, our team can tackle every aspect of the wet-lab. In addition to our hands-on laboratory and analysis experts, we have the medical and clinical domain knowledge to guarantee that your tests are handled in a safe and compliant manner. Coupled with our business team and understanding of how to deliver tests that address your specific needs, we deliver the ultimate experience. Through our cutting-edge biotechnology, we offer a full spectrum of tailored and affordable genetic testing services.
+
Featured
myDNA Pharmacogenomic Test
... Pharmacogenomic Testing is enabling doctors to predict whether a patient may have a poor response or higher risk of side effects before prescribing medications. Gene by Gene is helping practitioners fast-track healthcare goals and enable personalization for every patient. ...
Cambridge, United Kingdom
1-10 Employees
HEPAprint is a predictive software solution that uses an individual patient's genes to help guide clinicians to make prescribing decisions that are safer for that patient. In essense, it is a prescribing decision support tool that helps clinicians risk stratify prescribing at the point-of-prescribing, in real time.
+
Featured
HEPAprint - Clinical Decision Making, Pharmacogenomics
... HEPAprint - Clinical Decision Making, Pharmacogenomics ...
Washington, United States
11-50 Employees
2019
Our more personalized and proactive care delivery model is designed to improve patient outcomes and drive clinical efficiency and value-based profitability. We partner with healthcare providers to deliver collaborative telehealth solutions to improve the quality of healthcare. Chronic diseases are a leading driver of healthcare costs. State-of-the-art devices used to capture real-time data to enable proactive clinical interventions. Supporting your patients during care transitions to reduce hospital readmissions. Pharmacological knowledge and disease management expertise mitigate medication-related risks and provide a source of education for patients with complex medication needs. Our technology platform is designed to seamlessly integrate with current EHR systems, provide advanced insights, predictive analytics and ensures secure HIPAA compliance. PharmD Live partners with physicians and other healthcare providers to deliver telehealth solutions for patients with multiple chronic conditions.
+
Featured
Pharmacogenomics
... Facilitating Pharmacogenomics research with evidence-based PGX data to create personalized, comprehensive, easy-to-read actionable ...
+
Featured
Pharmacogenomics in Houston, Texas
... Pharmacogenomics in Houston, ...
Tulsa, United States
1-10 Employees
We are working with numerous colleges and universities across the country, providing FDA/EUA approved COVID-19 PCR testing with next day results. Molecular (PCR) and Genetics Laboratory offering COVID-19 PCR Testing, Hereditary Cancer Testing(CGx) and Pharmacogenomics Testing(PGx). However, certain patterns that are seen in members of a family—such as the types of cancer that develop, other non-cancer conditions that are seen, and the ages at which cancer typically develops—may suggest the presence of an inherited susceptibility to cancer. Pharmacogenomics is the study of how genes affect a person’s response to drugs. We’re dedicated to innovation and to consistently improve the experience for Physicians, Hospitals, Treatment Centers, and Patients. We thrive to provide the most accurate results and pride ourselves on our customer service to exceed the satisfaction of our clients.
+
Featured
About Us | Lucid Laboratory | United States
... Genetic testing for Hereditary Cancer Testing(CGx) and Pharmacogenomics Testing(PGx) ...
Atlanta, United States
11-50 Employees
2019
In the next chapter of LUX Diagnostics, we are bringing that same emphasis on innovation and speed to the traditional laboratory testing market.
+
Featured
Pharmacogenomics (PGX)
... Learn more about LUX Diagnostics PGx pharmacogenomics testing services for creating precision healthcare solutions based on genetic factors. ...
Houston, United States
1-10 Employees
2019
Build a collaborative, patient-focused drug therapy partnership among providers & pharmacist practitioners. Optimize patient drug therapy outcomes & safeguard medication use. More now than ever, clinicians rely heavily on pharmacists to provide support in medication therapy management (MTM). With the COVID-19 pandemic still on the rise. Obtaining organizational health care accreditation is a huge accomplishment.
+
Featured
inPHARM Consulting - GET inPHARMD NOW!
... Pharmacogenomic (PGx) Testing & ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Pharmacogenomic
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 56 |
| Amount of suitable service providers | 81 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1942 |
| Youngest suiting company | 2020 |
20%
40%
60%
80%
Pharmacogenomics is a scientific discipline at the intersection of pharmacology and genomics that focuses on understanding how an individual's genetic makeup affects their response to drugs. This field aims to optimize drug therapy, with respect to the genes that govern drug metabolism and action, for maximum efficacy and minimal adverse effects. Pharmacogenomics seeks to elucidate the genetic basis for the wide variability observed in drug response among individuals, thereby facilitating the development of personalized medicine. Through the identification of genetic markers that predict drug response, it enables the tailoring of drug choice and dosage to the genetic profile of an individual, thus heralding a move away from the "one-size-fits-all" approach in pharmacotherapy. This personalized approach not only enhances therapeutic effectiveness but also significantly reduces the risk of drug toxicity and adverse reactions. In clinical practice, pharmacogenomic testing can guide the selection of optimal therapeutic agents for a range of conditions, from cardiovascular diseases to cancer, thereby improving patient outcomes. Moreover, in drug development, pharmacogenomics contributes to the design of targeted therapies and helps in identifying patient populations who are most likely to benefit from a new medication, streamlining clinical trials. The impact of pharmacogenomics is profound, promising to transform healthcare by making it more precise, predictive, and personalized.
1. Enhanced Drug Efficacy and Safety
: Pharmacogenomics allows for the customization of drug treatment to each individual's genetic makeup, significantly increasing the effectiveness of medications. This personalized approach helps in identifying the most suitable drug and dosage, reducing the trial-and-error process often associated with traditional prescription methods. Consequently, patients are less likely to experience adverse drug reactions, enhancing overall treatment safety.
2. Improved Drug Discovery and Development
: By understanding genetic factors that influence patient responses to medications, pharmacogenomics guides pharmaceutical companies in developing targeted therapies. This specialization in drug development can lead to the creation of more effective treatments with fewer side effects, accelerating the path from research to market.
3. Cost-Effectiveness
: Although the initial costs of pharmacogenomic testing may seem high, the long-term benefits include reduced healthcare costs. By optimizing drug selection and dosing from the outset, there are fewer hospitalizations due to adverse drug reactions and less money spent on ineffective medications, making healthcare more cost-effective over time.
4. Advancement in Precision Medicine
: Pharmacogenomics is a cornerstone of precision medicine, which aims to tailor healthcare, with medical decisions and treatments being customized to the individual patient. This approach moves away from the one-size-fits-all strategy, leading to more precise, predictable, and potent healthcare solutions.
While evaluating the different suppliers make sure to check the following criteria:
1. Accreditation and Certifications
Ensure the supplier has the necessary accreditations from recognized health and quality organizations. This confirms their adherence to industry standards and regulations.
2. Technology and Equipment
Evaluate the technology and equipment used for pharmacogenomic testing. Advanced technology ensures higher accuracy, reliability, and efficiency of tests.
3. Experience and Expertise
Consider the supplier's experience and the expertise of their staff in pharmacogenomics. Experienced suppliers are more likely to provide accurate and comprehensive analysis.
4. Data Security and Privacy
Check the supplier’s policies on data security and patient privacy. It’s crucial that the supplier complies with laws and regulations protecting patient information.
5. Turnaround Time
Inquire about the turnaround time for test results. Faster results can lead to quicker decision-making in clinical settings.
6. Customer Support
Evaluate the level of customer support offered. Effective communication and support are essential for resolving any issues and clarifying test results.
7. Cost and Insurance Coverage
Consider the cost of services and whether they accept insurance. Competitive pricing and insurance acceptance can make pharmacogenomic testing more accessible.
8. Clinical Validity and Utility
Ensure the tests offered have clinical validity and utility. Tests should be backed by scientific evidence demonstrating their relevance and effectiveness in patient care.
Pharmacogenomics, the study of how genes affect a person's response to drugs, is revolutionizing personalized medicine and has significant B2B applications across various industries. In the pharmaceutical industry, pharmacogenomics aids in the design and development of new drugs. By understanding genetic factors that influence drug metabolism, companies can tailor medications to improve efficacy and reduce adverse effects, leading to more successful clinical trials and faster regulatory approval. This genetic insight accelerates the path to market for new therapies and enhances drug safety profiles. Healthcare providers and diagnostic companies benefit by offering pharmacogenomic testing services. These tests help clinicians predict which medications and dosages will be most effective for their patients based on genetic makeup, thereby optimizing treatment plans. For diagnostic companies, this opens up a new product line and revenue stream, while healthcare providers can improve patient outcomes and satisfaction, reducing the risk of trial-and-error prescribing. Insurance companies and corporate wellness programs are also leveraging pharmacogenomics to minimize healthcare costs and improve employee health. By supporting personalized medicine initiatives, insurers can reduce the incidence of adverse drug reactions and ineffective treatments, leading to lower healthcare claims. Meanwhile, corporate wellness programs that include pharmacogenomic testing can enhance employee health and productivity by ensuring that employees receive the most effective treatments from the start. Lastly, the biotechnology research sector uses pharmacogenomics to explore genetic variations and their implications in diseases and treatment responses. This research underpins the development of targeted therapies and contributes to the growing field of precision medicine, opening up collaboration and funding opportunities with pharmaceutical companies and academic institutions. Together, these use cases demonstrate pharmacogenomics' transformative potential across industries, from improving drug development and personalized treatment plans to enhancing healthcare outcomes and reducing costs.
As of the latest information available, pharmacogenomics, the study of how genes affect a person's response to drugs, spans various Technology Readiness Levels (TRLs) depending on the specific application and context, with significant aspects ranging from TRL 4 (technology validated in a lab) to TRL 7 (demonstration in an operational environment). This broad spectrum is due to the multifaceted nature of pharmacogenomics, which includes drug discovery, personalized medicine, and the development of genetic tests to predict drug efficacy and side effects. The reason for this wide range in TRLs lies in the technical challenges and advancements in the field. On one end, laboratory-based validations of pharmacogenomic markers have shown promising results, indicating a mature understanding of certain genetic influences on drug metabolism and efficacy. However, translating these findings into widely accepted clinical practices and integrating them into healthcare systems represents a higher hurdle, requiring extensive clinical trials, regulatory approval, and systems integration, thus placing these applications at a lower TRL. The differential TRLs reflect both the rapid pace of technological and scientific advancement in genetic sequencing and analysis, and the more deliberate pace of clinical validation, regulatory considerations, and public acceptance.
In the short-term, the focus in pharmacogenomics will be on expanding accessible genetic testing kits and integrating these findings into electronic health records (EHRs). This will enable healthcare providers to make informed medication decisions based on a patient's genetic makeup, reducing the trial-and-error approach in prescribing medications. Advances in machine learning will also enhance the predictive capabilities of pharmacogenomic tools, allowing for more precise identification of individuals at risk of adverse drug reactions. In the mid-term, we will see the development of more sophisticated pharmacogenomic applications, including the integration of artificial intelligence (AI) to analyze complex genetic data in real-time. This period will also witness the expansion of pharmacogenomic databases, including diverse populations to address ethnic and racial disparities in genetic research. Personalized drug development, tailored to specific genetic profiles, will start to emerge, leading to more effective and targeted therapies with fewer side effects. Long-term advancements will revolutionize healthcare through the widespread adoption of pharmacogenomics in routine clinical practice. This will include the development of universal pharmacogenomic screening at birth, leading to lifelong personalized medication strategies. Additionally, we will see the creation of highly customized drugs designed for individuals based on comprehensive genetic, environmental, and lifestyle data. This era will mark the pinnacle of precision medicine, with pharmacogenomics playing a central role in achieving optimal therapeutic outcomes for patients worldwide.
Some interesting questions that has been asked about the results you have just received for Pharmacogenomic
What are related technologies to Pharmacogenomic?
Based on our calculations related technologies to Pharmacogenomic are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Pharmacogenomic?
Start-Ups who are working in Pharmacogenomic are Rapid Dx Laboratory
Which industries are mostly working on Pharmacogenomic?
The most represented industries which are working in Pharmacogenomic are Health Care, Biotechnology, Science and Engineering, Information Technology, Professional Services
How does ensun find these Pharmacogenomic Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
